Eledon Pharmaceuticals, Inc. (ELDN) dividends
ELDN on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Eledon Pharmaceuticals, Inc. dividend: key facts
Own Eledon Pharmaceuticals, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next ELDN dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Results, reports and dividend announcements
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights13 Nov 2026 · GlobeNewsWire
Planned global Phase 3 LEGACY trial of tegoprubart in kidney transplantation remains on track to initiate in Q4 2026 FDA cleared the Company's IND application for a planned registrational path study o...
- Eledon Pharmaceuticals presents patient-reported outcomes data from BESTOW trial26 Oct 2026 · TheFly
Eledon Pharmaceuticals (ELDN) announced new patient-reported outcomes data from the Phase 2 BESTOW clinical trial of tegoprubart, its novel investigational immunosuppression therapy. The data showed s...
- Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting26 Oct 2026 · GlobeNewsWire
Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occ...
- Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting10 Oct 2026 · GlobeNewsWire
IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (âEledonâ) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephr...
- Eledon Pharmaceuticals updates long-term data from Phase 2 BESTOW trial26 Sep 2026 · TheFly
Eledon Pharmaceuticals (ELDN) announced updated long-term data from its Phase 2 BESTOW clinical program evaluating tegoprubart in patients undergoing kidney transplantation, presented at the Internati...
- Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society26 Sep 2026 · GlobeNewsWire
Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolim...
- Eledon files islet cell transplant application, plans Phase 3 kidney trial15 Sep 2026 · TheFly
Eledon Pharmaceuticals (ELDN) announced significant progress across multiple tegoprubart development programs in kidney allotransplantation and islet cell transplantation. Eledon has submitted an Inve...
- Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society15 Sep 2026 · GlobeNewsWire
IRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (âEledonâ) (Nasdaq: ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of tegopru...
Insufficient verified data for a financial-health score
Dividend data and price last updated 18 Nov 2026.